Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB
Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026

Vinge advises SEB Kort in connection with a cross-border merger with AirPlus

Vinge advised SEB Kort in connection with a cross-border merger whereby the subsidiary AirPlus has been absorbed into SEB Kort.
August 06, 2026

Vinge advises Altor- and Stena-owned Gunnebo in connection with the divestment of Gunnebo Entrance Control AB to ASSA Abloy

 Vinge has advised Gunnebo in connection with its divestment of Gunnebo Entrance Control AB to ASSA Abloy.
August 04, 2026